Caris Life Sciences, Inc Common Stock

Yahoo Finance • 20 days ago

Three Stocks Estimated To Be Priced Below Intrinsic Value In March 2026

Over the last 7 days, the United States market has experienced a 2.3% decline, yet it remains up by 13% over the past year with earnings projected to grow by 16% annually. In this context, identifying stocks that are potentially priced bel... Full story

Yahoo Finance • 29 days ago

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Stocks Settle Lower as Bank Shares Tumble and Tech Stocks Fall

The S&P 500 Index ($SPX) (SPY) on Friday closed down -0.43%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.05%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.30%.  March E-mini S&P futures (ESH26) fell -0.47%, and M... Full story

Yahoo Finance • 2 months ago

Stocks Retreat on AI Disruption Concerns and Geopolitical Risks

The S&P 500 Index ($SPX) (SPY) today is down -0.61%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -1.17%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.41%.  March E-mini S&P futures (ESH26) are down -0.59%, and March E-mini... Full story

Yahoo Finance • 2 months ago

3 Stocks That May Be Undervalued By Market Estimates In February 2026

As February 2026 begins, U.S. stock markets have shown a strong start with major indices like the Dow Jones and S&P 500 ending sharply higher, reflecting investor optimism despite recent economic uncertainties such as delayed jobs data and... Full story

Yahoo Finance • 5 months ago

European Penny Stocks To Watch In November 2025

As European markets navigate a period of mixed performance, with the STOXX Europe 600 Index recently pulling back from a fresh high, investor focus remains on the economic landscape shaped by steady interest rates and near-target inflation... Full story

Yahoo Finance • 6 months ago

Elevance Health Inc: A Key Exit in Eaton Vance Worldwide Health Sciences Fund's Q3 2025 Portfolio

This article first appeared on GuruFocus. Insights into Eaton Vance's Strategic Moves in the Healthcare Sector Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) recently submitted its N-PORT filing for the third quarter of 2... Full story

Yahoo Finance • 6 months ago

Caris Life Sciences, Inc. (CAI) Soars 81% YoY with $181M Q2 Revenue

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. Caris Life Sciences, Inc. is one of them. Caris Life Sciences, Inc. (NASDAQ:CAI) is advancing its position as a leader in precision medicine by combining... Full story

Yahoo Finance • 6 months ago

CAI and Valkit.ai Form Strategic Partnership to Advance Gen2 AI-Augmented Validation (DVT) in Life Sciences

Indianapolis, IN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- CAI, a global leader in operational readiness and excellence for life sciences and mission critical facilities, today announced a strategic partnership with Valkit.ai, a fast-growing i... Full story

Yahoo Finance • 7 months ago

CAI Achieves SOC 2 Type II Certification, Strengthening Trust of Data Management

ALLENTOWN, Pa., Sept. 18, 2025 (GLOBE NEWSWIRE) -- CAI, a global services firm, today announced it achieved the System and Organization Controls (SOC) 2 Type II certification, validating its ability to protect sensitive client data amids... Full story

Yahoo Finance • 7 months ago

Strong Performance Lifted Caris Life Sciences (CAI) in Q2

ClearBridge Investments, an investment management company, released its “ClearBridge Select Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equities strongly rebounded in the second quarter.... Full story

Yahoo Finance • 7 months ago

Caris Life Sciences, Inc. (CAI) Secures FDA Nod for Revolutionary Tumor Profiling Test

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Caris Life Sciences, Inc. stands tenth among them. Caris Life Sciences, Inc. (NASDAQ:CAI) is a biotech company that is driven by its breakt... Full story

Yahoo Finance • 8 months ago

Can AI make clinical trials better?

Investing.com -- Clinical trials are notorious for being expensive and slow, with rising costs and declining efficiency. According to Bernstein, industry R&D spending grew 44% between 2012 and 2022, while the number of novel drug approvals... Full story

Yahoo Finance • 8 months ago

Cathie Wood's ARK buys Archer Aviation, sells Kratos Defense stock

Cathie Wood’s ARK ETFs have made notable moves in the market on Tuesday, 12 August 2025, with a series of buys and sells that signal the investment firm’s strategic adjustments. The most significant transaction of the day involved the sale... Full story

Yahoo Finance • 9 months ago

Cathie Wood's ARK buys Tesla, sells Coinbase in latest trades

Cathie Wood’s ARK ETFs have made a series of notable trades on Tuesday, 15 July 2025, with Tesla Inc (NASDAQ:TSLA) and Coinbase Global Inc (NASDAQ:COIN) taking center stage as the most significant transactions by dollar value. The invest... Full story

Yahoo Finance • 9 months ago

Cathie Wood's ARK sells Roku, buys Caris Life Sciences stock

Cathie Wood’s ARK ETFs have published their daily trades for Monday, July 14th, 2025, revealing a mix of strategic buy and sell actions across various sectors. Leading the trades was the sale of Roku Inc (NASDAQ:ROKU) stock, with a combi... Full story

Yahoo Finance • 9 months ago

Caris Life Sciences stock initiated with Buy rating at BTIG on precision oncology leadership

Investing.com - BTIG initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with a Buy rating and a price target of $38.00 on Monday, representing significant upside from the current price of $26.51. According to InvestingPro data, a... Full story

Yahoo Finance • 9 months ago

BofA Securities initiates coverage on Caris Life Sciences stock with Buy rating

Investing.com - BofA Securities initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with a Buy rating and a price target of $31.00 on Sunday, representing a potential 17% upside from the current price of $26.51. According to Inves... Full story

Yahoo Finance • 9 months ago

Catalyst Watch: Bank earnings rush, OPEC report, Tesla EVs get Grok, and Superman at the box office

[Wall Street sign in Lower Manhattan, NYC] georgeclerk Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MO... Full story

Yahoo Finance • 9 months ago

Will Insiders Be Tempted To Buy More CAI At The New 52-Week Low?

In trading on Monday, shares of Caris Life Sciences Inc (Symbol: CAI) touched a new 52-week low of $25.40/share. That's a $5.30 share price drop, or -17.26% decline from the 52-week high of $30.70 set back on 06/20/2025. Large percentage... Full story